News Sentiment

PBYI sentiment intelligence

Puma Biotechnology Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 8.00 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-3.1% over one week, +9.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Market Reaction

Balanced read

59/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -3.1% Price reacting lower
Trend fit Trend active 9.1% over four weeks
Fair value 82.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 32
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingView 9
Stock Titan 7
Investing.com 3
simplywall.st 3
www.marketscreener.com 2
TradingKey 2
Investing.com Canada 1

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 19
Analyst action 2
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
Stock Titan Direct company coverage

[144] PUMA BIOTECHNOLOGY, INC. SEC Filing

This article details a PUMA BIOTECHNOLOGY, INC. SEC Filing of Form 144, indicating a proposed sale of securities. The filing shows that 9,386 shares of common stock, valued at $77,554.64, are to be sold through Fidelity Brokerage Services LLC, originating from restricted stock ve

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 09:11
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Puma Biotechnology Inc For: 8 July By Investing.com

This article reports on a Form 4 filing for Puma Biotechnology Inc. dated July 8. Form 4s disclose transactions by insiders, but the article does not provide specific details from the filing. It briefly mentions Puma Biotechnology Inc. (PBYI) and its current stock performance.

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 07:10
Source
Investing.com Canada
Investing.com Direct company coverage

Puma Biotechnology’s Douglas M. Hunt sells $69,904 in shares

Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, sold 8,460 shares of the company's stock for $69,904. This transaction took place as part of a pre-arranged plan, with the stock trading near its 52-week high after a significant gain. Despite thi

Tone
Negative 39/100
Event
Regulatory and legal
Published
09 Jul 2026 07:10
Source
Investing.com
Investing.com Direct company coverage

Puma biotechnology CFO Maximo Nougues sells $77,556 in stock

Maximo F. Nougues, CFO of Puma Biotechnology, Inc. (NASDAQ:PBYI), sold 9,386 shares of company stock for $77,556 on July 6, 2026. This transaction was part of a pre-established sell-to-cover program, leaving Nougues with 230,637 shares. The sale occurred while PBYI stock was near

Tone
Negative 36/100
Event
Market update
Published
09 Jul 2026 07:10
Source
Investing.com
Investing.com Nigeria Direct company coverage

Alan Auerbach, Puma Biotechnology president and CEO, sells $364,051 By Investing.com

Alan Auerbach, President and CEO of Puma Biotechnology (NASDAQ:PBYI), sold 44,058 shares of company stock for $364,051 on July 6, 2026, under a pre-established trading plan. This sale occurred while the stock was near its 52-week high, having gained 126% in the past year, though

Tone
Negative 42/100
Event
Market update
Published
09 Jul 2026 01:30
Source
Investing.com Nigeria
Stock Titan Direct company coverage

PUMA Biotechnology (PBYI) officer Douglas Hunt sells 8,460 shares under 10b5-1 plan

Douglas M. Hunt, an officer at PUMA Biotechnology (PBYI), reported an open-market sale of 8,460 shares of company stock at an average price of $8.263 per share. This transaction was conducted under a Rule 10b5-1(c) sell-to-cover plan established on December 14, 2020. Following th

Tone
Negative 39/100
Event
Market update
Published
09 Jul 2026 00:43
Source
Stock Titan
Stock Titan Direct company coverage

Puma Biotechnology (PBYI) CFO sells 9,386 shares in 10b5-1 trade

Puma Biotechnology's CFO, Maximo F. Nougues, sold 9,386 shares of common stock on July 6, 2026, for $8.263 per share, totaling approximately $78,000. This transaction was conducted under a pre-arranged Rule 10b5-1(c) sell-to-cover plan established in December 2020. After the sale

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 23:43
Source
Stock Titan
Stock Titan Direct company coverage

Puma Biotechnology (PBYI) CEO sells 44,058 shares under 10b5-1 plan

Puma Biotechnology's President and CEO, Alan H. Auerbach, sold 44,058 shares of common stock at $8.263 per share on July 6, 2026. This transaction was conducted under a pre-established Rule 10b5-1(c) sell-to-cover program adopted in December 2020. Following the sale, Auerbach sti

Tone
Negative 40/100
Event
Market update
Published
08 Jul 2026 00:43
Source
Stock Titan
Stock Titan Direct company coverage

PUMA BIOTECHNOLOGY, INC. SEC Filing

This article reports on a Form 144 SEC filing by Puma Biotechnology, Inc. (PBYI), indicating a proposed sale of securities under Rule 144. The filing details the acquisition of 44,058 shares through restricted stock vesting on July 1, 2026, and their intended sale on July 6, 2026

Tone
Neutral 50/100
Event
Deals and strategy
Published
06 Jul 2026 20:40
Source
Stock Titan
Finviz Direct company coverage

PBYI - Puma Biotechnology Inc Latest SEC Filings

This article provides comprehensive financial data and performance metrics for Puma Biotechnology Inc (PBYI), including its latest stock close, market capitalization, income, sales, and various ratios. It also details insider and institutional ownership, analyst recommendations,

Tone
Neutral 50/100
Event
Analyst action
Published
04 Jul 2026 18:09
Source
Finviz
TradingView Direct company coverage

Price to sales forward of Puma Biotechnology Inc – NASDAQ:PBYI

The article provides a snapshot of Puma Biotechnology Inc. (NASDAQ: PBYI) on TradingView, focusing on its "Price to sales forward" metric. It indicates that the market was closed at the time of viewing, with no trades, and offers various data points like financials, news, and tec

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 13:40
Source
TradingView
Ad-hoc-news.de Direct company coverage

Puma Biotechnology highlights targeted cancer therapies as investors watch Nasdaq-listed PBYI

Puma Biotechnology is a Nasdaq-listed biopharmaceutical company focusing on targeted oncology therapies, particularly for HER2-positive breast cancer. The company's strategy involves commercializing its approved drug while investing in pipeline development for additional indicati

Tone
Positive 66/100
Event
Market update
Published
03 Jul 2026 12:09
Source
Ad-hoc-news.de
Stock Titan Direct company coverage

Puma Biotechnology awards stock to four new employees

Puma Biotechnology, Inc. announced the grant of 31,625 restricted stock unit awards to four new non-executive employees. These awards are an inducement for new hires and will vest over a three-year period, with the first portion vesting on July 1, 2026, and subsequent portions ev

Tone
Positive 63/100
Event
Market update
Published
03 Jul 2026 07:10
Source
Stock Titan
BioSpace Direct company coverage

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - July 2, 2026

Puma Biotechnology (NASDAQ: PBYI) announced inducement restricted stock unit awards covering 31,625 shares to four new non-executive employees, approved by its Compensation Committee on July 1, 2026. These awards, granted under the company's 2017 plan, vest over three years, with

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 04:09
Source
BioSpace
marketscreener.com Direct company coverage

Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Small Cap Comp Growth Benchmark

Puma Biotechnology, Inc. (NasdaqGS:PBYI), a biopharmaceutical company focusing on cancer care, has been added to the Russell Small Cap Comp Growth Benchmark, as well as several other Russell Growth benchmarks on June 29, 2026. This news follows previous announcements earlier in t

Tone
Positive 70/100
Event
Market update
Published
30 Jun 2026 16:12
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 2500 Growth Benchmark

Puma Biotechnology, Inc. (NasdaqGS: PBYI) has been added to the Russell 2500 Growth Benchmark, as well as several other Russell indices including the Russell Small Cap Comp Growth Benchmark, Russell 2000 Growth Benchmark, and Russell 3000E Growth Benchmark. This news comes shortl

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 19:41
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 3000E Growth Benchmark

Puma Biotechnology, Inc. (PBYI) has been added to the Russell 3000E Growth Benchmark. This news follows a previous announcement that the company was also added to the Russell 2000 Growth Benchmark on the same day. Puma Biotechnology specializes in developing and commercializing p

Tone
Positive 67/100
Event
Market update
Published
29 Jun 2026 12:06
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to revenue forward of Puma Biotechnology Inc – BOATS:PBYI

This article provides a financial snippet for Puma Biotechnology Inc (PBYI), specifically its enterprise value to revenue forward metric. The content highlights the stock's market status as closed with no recent trades and is presented within the TradingView platform.

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 03:10
Source
TradingView
TradingView Direct company coverage

PBYI Forecast — Price Target — Prediction for 2027

This article provides a forecast for Puma Biotechnology Inc (PBYI) stock, including analyst price targets and historical performance data. One analyst projects a maximum and minimum price target of $5.00 for PBYI. The stock has shown significant increases over the past year, and

Tone
Neutral 50/100
Event
Analyst action
Published
28 Jun 2026 15:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of Puma Biotechnology Inc – NASDAQ:PBYI

This article provides financial information for Puma Biotechnology Inc (NASDAQ: PBYI), specifically its price-to-book forward ratio. It highlights that the market was closed at the time of access and contains no active trades or specific current values. The content appears to be

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 09:09
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Puma Biotechnology Inc – BOATS:PBYI

This article provides financial information for Puma Biotechnology Inc (PBYI), specifically its price to sales forward metric. The content indicates that the market is currently closed with no trades. It also links to various TradingView features and legal information.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 21:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Puma Biotechnology Inc – BOATS:PBYI

This article displays an enterprise value to EBITDA forward metric for Puma Biotechnology Inc (PBYI), as presented by Blue Ocean Alternative Trade System (BOATS) on TradingView. The page primarily showcases financial data with no specific values or analytical commentary provided

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 08:09
Source
TradingView
TradingView Direct company coverage

Puma Biotechnology, Inc. Actuals & Estimates (NASDAQ:PBYI)

This article provides actual and estimated financial data for Puma Biotechnology Inc (NASDAQ: PBYI), covering its stock performance, analyst forecasts, and various financial metrics. It details the company's current stock price, market capitalization, earnings, revenue, and histo

Tone
Positive 62/100
Event
Earnings
Published
26 Jun 2026 15:09
Source
TradingView
TradingKey Direct company coverage

Puma Biotechnology Inc (PBYI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

Puma Biotechnology Inc (PBYI) currently has a price momentum score of 7.50, ranking 73rd in the Pharmaceuticals industry. The stock is trading between a resistance level of 8.46 and a support level of 6.83, suggesting potential for range-bound swing trading. Technical indicators

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 13:41
Source
TradingKey
Stock Titan Direct company coverage

PBYI SEC Filings - Puma Biotechnology Inc 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Puma Biotechnology Inc. (PBYI) SEC filings, including annual 10-K reports, quarterly 10-Q reports, and material 8-K events. These filings offer insights into the company's financials, corporate governance, and oncology programs. The

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 13:09
Source
Stock Titan
TradingKey Direct company coverage

Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Puma Biotechnology Inc (PBYI) currently holds an earnings forecast score of 6.00, placing it 132nd out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $5.00 for PBYI, with an expected revenue of $53.00 million for the next quarter. The consens

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 05:39
Source
TradingKey